Sartorius Stedim Biotech (SDMHF) Stock News, Oct 20, 2020

Sartorius Stedim Biotech reported strong growth in the first nine months of 2020, with sales revenue rising by 29.2% to 1,379.4 million euros. This growth was driven by high demand for its products, recent acquisitions, and pandemic-related increases in biopharmaceutical production capacities. Order intake surged by 43.9% to 1,637.9 million euros. The group’s underlying EBITDA grew by 39.2% to 434.7 million euros, with a margin increase to 31.5%. The company expects to achieve growth at the upper end of its forecast for 2020 despite uncertainties due to the pandemic.